Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and...

por Staab, Thomas, Isbary, Georg, Amelung, Volker E., Ruof, Jörg
Publicado 2016

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the F...

por Ruof, Jörg, Staab, Thomas, Dintsios, Charalabos-Markos, Schröter, Jakob, Schwartz, Friedrich Wilhelm
Publicado 2016

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations

por Staab, Thomas R., Walter, Miriam, Mariotti Nesurini, Sonja, Dintsios, Charalabos-Markos, Graf von der Schulenburg, J.-Matthias, Amelung, Volker E., Ruof, Jörg
Publicado 2018